On 14 December 2015, orphan designation (EU/3/15/1587) was granted by the European Commission to Diamond BioPharm Limited, United Kingdom, for combretastatin A1 diphosphate for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.
The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.
Combretastatin A1 diphosphate-
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.